Effects of the selective 5-HT(2A) receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats

Neuropsychopharmacology

Volumn 15, Issue 2, 1996, Pages 116-124

  Kehne, J H ^a   Ketteler, H J ^a   McCloskey, T C ^a   Sullivan, C K ^a   Dudley, M W ^a   Schmidt, C J ^a  

^a SANOFI   (France)

Author keywords

5 HT(2A) receptor antagonist; Antipsychotic; Locomotion; MDL 100,907; MDMA; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; HALOPERIDOL; MDL 28133A; METITEPINE; NEUROLEPTIC AGENT; PROPRANOLOL; RITANSERIN; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DOPAMINE RELEASE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; SEROTONIN RELEASE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030222260     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00160-F     Document Type: Article

References (23)

1. Callaway CW, Wing LL, Geyer MA (1990): Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exper Therap 254:456-464
2. 1-like receptors mediate hyperactivity in rats induced by 3,4-methylenedioxymethamphetamine. Neuropsychopharmacology 7:113-127
3. 2 antagonism of amphetamine-induced facilitation of brain stimulation reward. Pharmacol Biochem Behav 52:799-804
4. Gold LH, Koob GF, Geyer MA (1988): Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. J Pharmacol Exper Therap 247:547-555
5. Hiramatsu M, Cho AK (1990): Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats. An in vivo microdialysis study. Neuropharmacology 29:269-275
6. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exper Therap 277:968-981
7. Kehne JH, McCloskey TC, Taylor VL, Black CK, Fadayel GM, Schmidt CJ (1992): Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats. J Pharmacol Exper Therap 260:78-89
8. 2 receptors. Psychopharmacology 112:S40-S54
9. Megens AHPA, Niemegeers CJE, Awouters FHL (1992): Antipsychotic profile and side-effect liability of haloperidol, risperidone, and ocaperidone as predicted from their differential interaction with amphetamine in rats. Drug Devel Res 26:129-145
10. 2 pK1 values. J Pharmacol Exper Therap 251:238-246
11. 2A antagonist. Behavioral Brain Research 73:163-167
12. 3-mediated control of dopaminergic function. In Kahn RS (ed), Proceedings of American College of Neuropsychology Symposium, Psychopharmacology 112:S60-S67
13. Paulus MP, Geyer MA (1991): A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology 104:6-16
14. 1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology 8: 201-211
15. Schecter MD (1988): Serotonergic-dopaminergic mediation of 3,4-methylenediosymethamphetamine (MDMA, "ecstasy"). Pharmacol Biochem Behav 31:817-824
16. Schmidt CJ, Kehne JH (1990): Neurotoxicity of MDMA: Neurochemical effects. Ann NY Acad Sci 600:665-681
17. 2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine. Europ J Pharmacol 220:151-159
18. 2 receptors exert a state-dependent regulation of dopaminergic function: Studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 223:65-74
19. 2 receptors in schizophrenia and antipsychotic activity. Internat Clin Psychopharmacol 8 (suppl 2):25-32
20. 2A receptors in antipsychotic activity. Life Sci 56:2209-2222
21. 2 antagonist MDL 100,907 as a putative atypical antipsychotic: Behavioral, electrophysiological, and neurochemical studies. J Pharmacol Exper Therap 266:1-8
22. 2 modulation of psychostimulant-induced facilitation of brain stimulation reward. Drug Develop Res 34:297-305
23. Yamamoto BK, Spanos LJ (1988): The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Europ J Pharmacol 148:195-203